Old Web
English
Sign In
Acemap
>
authorDetail
>
Joshua Ray
Joshua Ray
Intensive care medicine
Erlotinib
Cell
Lung cancer
Population
2
Papers
43
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
2012
ClinicoEconomics and Outcomes Research
A. Vergnenegre
Joshua Ray
C. Chouaid
Francesco Grossi
Helge Bischoff
David F. Heigener
S Walzer
Show All
Source
Cite
Save
Citations (24)
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
2012
ClinicoEconomics and Outcomes Research
Silke Walleser
Joshua Ray
Helge Bischoff
A. Vergnenegre
Hubertus Rosery
C. Chouaid
David F. Heigener
Javier de Castro-Carpeño
Marcello Tiseo
S Walzer
Show All
Source
Cite
Save
Citations (19)
1